128 related articles for article (PubMed ID: 32914624)
1. Discovery of Novel Pyrazolo[3,4-
Hu L; Li L; Chang Q; Fu S; Qin J; Chen Z; Li X; Liu Q; Hu G; Li Q
J Med Chem; 2020 Oct; 63(19):11215-11234. PubMed ID: 32914624
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats.
Cheng Y; Gong Y; Qian S; Mou Y; Li H; Chen X; Kong H; Xie W; Wang H; Zhang Y; Huang Z
J Med Chem; 2018 Feb; 61(4):1474-1482. PubMed ID: 29377691
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
Li L; Zhang W; Lin F; Lu X; Chen W; Li X; Zhou X; Su R; Wang L; Zheng Z; Li S
Eur J Med Chem; 2019 Jul; 173():107-116. PubMed ID: 30995566
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
5. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.
Deruelle P; Balasubramaniam V; Kunig AM; Seedorf GJ; Markham NE; Abman SH
Biol Neonate; 2006; 90(2):135-44. PubMed ID: 16582538
[TBL] [Abstract][Full Text] [Related]
6. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
7. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
Huh JW; Kim SY; Lee JH; Lee YS
Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997
[TBL] [Abstract][Full Text] [Related]
8. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
Thorsen LB; Eskildsen-Helmond Y; Zibrandtsen H; Stasch JP; Simonsen U; Laursen BE
Eur J Pharmacol; 2010 Nov; 647(1-3):147-54. PubMed ID: 20828552
[TBL] [Abstract][Full Text] [Related]
9. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S
Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452
[TBL] [Abstract][Full Text] [Related]
11. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
12. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
13. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
Dumitrascu R; Weissmann N; Ghofrani HA; Dony E; Beuerlein K; Schmidt H; Stasch JP; Gnoth MJ; Seeger W; Grimminger F; Schermuly RT
Circulation; 2006 Jan; 113(2):286-95. PubMed ID: 16391154
[TBL] [Abstract][Full Text] [Related]
14. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Mittendorf J; Weigand S; Alonso-Alija C; Bischoff E; Feurer A; Gerisch M; Kern A; Knorr A; Lang D; Muenter K; Radtke M; Schirok H; Schlemmer KH; Stahl E; Straub A; Wunder F; Stasch JP
ChemMedChem; 2009 May; 4(5):853-65. PubMed ID: 19263460
[TBL] [Abstract][Full Text] [Related]
15. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2019; 122-123():106599. PubMed ID: 31629919
[TBL] [Abstract][Full Text] [Related]
16. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
18. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
Rai N; Veeroju S; Schymura Y; Janssen W; Wietelmann A; Kojonazarov B; Weissmann N; Stasch JP; Ghofrani HA; Seeger W; Schermuly RT; Novoyatleva T
Biomed Res Int; 2018; 2018():3293584. PubMed ID: 29511676
[TBL] [Abstract][Full Text] [Related]
19. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
[TBL] [Abstract][Full Text] [Related]
20. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
